NCT06536868View on ClinicalTrials.gov

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).

DRUG

Etoposide

Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).

DRUG

Carboplatin or Cisplatin

Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).

RADIATION

Thoracic radiotherapy

IMRT 30-45Gy/10-15f

Trial Locations (6)

048000

RECRUITING

Jincheng General Hospital, Jincheng

032000

RECRUITING

Jinzhong third people's hospital, Jinzhong

030000

RECRUITING

Second Hospital of Shanxi Medical University, Taiyuan

RECRUITING

Shanxi Bethune Hospital, Taiyuan

RECRUITING

Shanxi Hospital of Traditional Chinese Medicine, Taiyuan

RECRUITING

TISCO General Hospital, Taiyuan

All Listed Sponsors
lead

Second Hospital of Shanxi Medical University

OTHER